PDS Biotechnology (PDSB) Other financing activities (2016 - 2025)
PDS Biotechnology's (PDSB) quarterly Other financing activities came in at $3.2 million in Q4 2025, up 308.87% YoY from $774091.0 in Q4 2024, and up 47.16% on a QoQ basis from $2.2 million in Q3 2025.
PDS Biotechnology (PDSB) Other financing activities (2016 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 9 years of Other financing activities data on file, last reported at $3.2 million in Q4 2025.
- Quarterly Other financing activities rose 308.87% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.3 million (up 586.72% YoY) and the FY2025 annual result came in at $5.3 million, up 586.72% from the prior year.
- Other financing activities climbed to $3.2 million in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3.2 million in Q4 2025 to a low of -$2.2 million in Q2 2025.
- A 5-year average of $530337.3 and a median of $123509.0 in 2021 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities slumped 99.98% — and 2022, when it jumped 934507.69%.
- Tracing PDSB's Other financing activities over 5 years: stood at $13.0 in 2021, then jumped by 934507.69% to $121499.0 in 2022, then surged by 146.99% to $300093.0 in 2023, then surged by 157.95% to $774091.0 in 2024, then soared by 308.87% to $3.2 million in 2025.
- The last three Other financing activities figures came in at $3.2 million (Q4 2025), $2.2 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.17 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | -2.15 Mn |
| Jun 30, 2025 | -2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 774,091.00 |
| Dec 31, 2024 | 774,091.00 |
| Dec 31, 2023 | 300,093.00 |
| Dec 31, 2023 | 300,093.00 |
| Jun 30, 2023 | 8,849.00 |
| Jun 30, 2023 | 8,849.00 |
| Dec 31, 2022 | 121,499.00 |
| Dec 31, 2022 | 121,499.00 |
| Jun 30, 2022 | 22,429.00 |
| Jun 30, 2022 | 22,429.00 |
| Mar 31, 2022 | 7,488.00 |
| Mar 31, 2022 | 7,488.00 |